New drug HU6 targets fatty liver disease in Mid-Stage trial
Disease control
Recruiting now
This study tests a new drug, HU6, in 180 adults aged 30 and older with MASH, a serious fatty liver condition. The goal is to see if HU6 is safe and can reduce liver fat compared to a placebo over 26 weeks. Participants will be randomly assigned to one of four groups, and neither …
Phase: PHASE2 • Sponsor: Rivus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 10:46 UTC